Moderna (NASDAQ:MRNA) Shares Sold Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 8/24/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/19/2026.
• Purchased $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/19/2026.
• Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/12/2026.
• Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 8/12/2026.
• Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 8/7/2026.
• Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.
• Purchased $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.

Moderna Stock Up 5.4%

MRNA opened at $143.97 on Friday. The stock has a market cap of $57.48 billion, a PE ratio of -18.02 and a beta of 1.10. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The business’s fifty day simple moving average is $92.35 and its 200 day simple moving average is $66.74.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period last year, the firm posted ($2.13) earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. As a group, research analysts expect that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MRNA. MUFG Securities EMEA plc purchased a new stake in Moderna in the second quarter worth approximately $28,000. Allied Private Wealth LLC bought a new position in shares of Moderna during the 2nd quarter valued at $30,000. Canton Hathaway LLC bought a new position in shares of Moderna during the 1st quarter valued at $31,000. Archer Investment Corp purchased a new position in shares of Moderna in the 2nd quarter worth $36,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Moderna by 148.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after buying an additional 801 shares during the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at $76,225,271.76. The trade was a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is currently owned by corporate insiders.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Momentum and upcoming data readouts supported the stock. Moderna rallied in Friday morning trading despite limited movement among peers. UBS reportedly identified three near-term “INT” data readouts, potentially giving investors multiple upcoming catalysts to anticipate. However, the reports did not provide detailed results or confirm that any readout will be positive. Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
• Neutral Sentiment: Congressional trading coverage offers no clear Moderna-specific catalyst. A report discussing recent stock transactions by members of Congress included Moderna-related investor-monitoring activity, but it did not identify a material change in the company’s outlook or operations. Congressional Stock Transactions
• Neutral Sentiment: Short-interest data appears unreliable. The report listed both current and prior short interest at zero and calculated a zero-day short-interest ratio, with an invalid percentage change. Therefore, it provides little useful information about short-covering or bearish positioning in Moderna.
• Negative Sentiment: Industry commercialization hurdles remain a risk. Manufacturing complexity and other barriers could slow the development and commercialization of personalized mRNA cancer vaccines, highlighting longer-term execution risks for Moderna and its peers. mRNA Cancer Vaccines’ Biggest Barriers to Market

Analysts Set New Price Targets

Several equities research analysts have weighed in on MRNA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a research report on Wednesday. UBS Group set a $81.00 target price on Moderna in a research note on Thursday, September 3rd. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Citigroup boosted their target price on Moderna from $41.00 to $60.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Finally, The Goldman Sachs Group lifted their price target on shares of Moderna from $67.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and a consensus price target of $76.72.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.